Di Paolo N, Capotondo L, Rossi P, Gaggiotti E, Pula G, Fanetti G
Department of Nephrology, Regional Hospital of Siena, Italy.
Nephron. 1989;52(3):268-72. doi: 10.1159/000185655.
Complex hemostatic changes in uremic patients are characterized by platelet distress and prolonged bleeding time. Dialysis corrects platelet function and improves the bleeding time but introduces a tendency to thrombophilia. The uremic patient is thus an excellent model for the evaluation of hemostatic drugs. VUEFFE (VF) is a new hemostatic agent which reduces bleeding time without modifying clotting parameters. Changes in hemostasis and coagulation were studied in 42 hemorrhagic uremic subjects in dialysis or on conservative management. The patients were divided into two groups, one of which was given oral VF and the other oral placebo. 84% of those receiving VF ceased bleeding within 15 days (compared to 25% for placebo) and there was a significant reduction in bleeding time. The drug can be given orally or parenterally, is well tolerated and without side effects, making it suitable for administration to hemorrhagic uremic patients.
尿毒症患者复杂的止血变化表现为血小板功能异常和出血时间延长。透析可纠正血小板功能并改善出血时间，但会引发血栓形成倾向。因此，尿毒症患者是评估止血药物的理想模型。VUEFFE（VF）是一种新型止血剂，可缩短出血时间而不改变凝血参数。我们对42例接受透析或保守治疗的出血性尿毒症患者的止血和凝血变化进行了研究。患者被分为两组，一组口服VF，另一组口服安慰剂。接受VF治疗的患者中84%在15天内止血（安慰剂组为25%），出血时间显著缩短。该药物可口服或胃肠外给药，耐受性良好且无副作用，适用于出血性尿毒症患者。
